{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:01:46Z","timestamp":1791021706069,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st","doi-asserted-by":"crossref","award":["2016001"],"award-info":[{"award-number":["2016001"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>In SSc, gastrointestinal tract (GIT) involvement is a major concern, with no disease-modifying and limited symptomatic therapies available. Faecal microbiota transplantation (FMT) represents a new therapeutic option for GIT-affliction in SSc, showing clinical promise in a recent controlled pilot trial. Here, we aim to investigate effects of FMT on duodenal biopsies collected from SSc patients by immunohistochemistry and transcriptome profiling.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed duodenal biopsies obtained pre-intervention (week 0) and post-intervention (weeks 2 and 16) from nine SSc patients receiving an intestinal infusion of FMT (n\u2009=\u20095) or placebo (n\u2009=\u20094). The analysis included immunohistochemistry (IHC) with a selected immune function and fibrosis markers, and whole biopsy transcriptome profiling.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In patients receiving FMT, the number of podoplanin- and CD64-expressing cells in the mucosa were lower at week 2 compared with baseline. This decline in podoplanin- (r\u2009=\u20090.94) and CD64-positive (r\u2009=\u20090.89) cells correlated with improved patient-reported lower GIT symptoms. Whole biopsy transcriptome profiling from week 2 showed significant enrichment of pathways critical for cellular and endoplasmic reticulum stress responses, microvillus and secretory vesicles, vascular and sodium-dependent transport, and circadian rhythm. At week 16, we found enrichment of pathways mandatory for binding activity of immunoglobulin receptors, T cell receptor complexes, and chemokine receptors, as well as response to zinc-ions. We found that 25 genes, including Matrix metalloproteinase-1 were upregulated at both week 2 and week 16.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Combining selective IHC and unbiased gene expression analyses, this exploratory study highlights the potential for disease-relevant organ effects of FMT in SSc patients with GIT involvement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, http:\/\/clinicaltrials.gov, NCT03444220.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead014","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T20:42:44Z","timestamp":1674333764000},"page":"2918-2929","source":"Crossref","is-referenced-by-count":8,"title":["Effects of faecal microbiota transplantation on the small intestinal mucosa in systemic sclerosis"],"prefix":"10.1093","volume":"62","author":[{"given":"Noemi","family":"Strahm","sequence":"first","affiliation":[{"name":"Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich , Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Didriksen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Rikshospitalet , Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0350-172X","authenticated-orcid":false,"given":"H\u00e5vard","family":"Fretheim","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Rikshospitalet , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind","family":"Molberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Rikshospitalet , Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind","family":"Midtvedt","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Rikshospitalet , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Nina","family":"Farstad","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo , Oslo, Norway"},{"name":"Department of Pathology, Oslo University Hospital, Rikshospitalet , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Midtvedt","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut E A","family":"Lundin","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo , Oslo, Norway"},{"name":"Department of Gastroenterology, Oslo University Hospital, Rikshospitalet , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Aabakken","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo , Oslo, Norway"},{"name":"Department of Gastroenterology, Oslo University Hospital, Rikshospitalet , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2521-3232","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"B\u0142yszczuk","sequence":"additional","affiliation":[{"name":"Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich , Schlieren, Switzerland"},{"name":"Department of Clinical Immunology, Jagiellonian University Medical College , Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-8310","authenticated-orcid":false,"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[{"name":"Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich , Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Kania","sequence":"additional","affiliation":[{"name":"Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich , Schlieren, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-7422","authenticated-orcid":false,"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Rikshospitalet , Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"2023080221015767700_kead014-B1","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/rheumatology\/keq147","article-title":"Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre","volume":"49","author":"Thoua","year":"2010","journal-title":"Rheumatology"},{"key":"2023080221015767700_kead014-B2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5301\/jsrd.5000214","article-title":"Gastrointestinal manifestations of systemic sclerosis","volume":"1","author":"Shreiner","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"2023080221015767700_kead014-B3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.rdc.2015.04.001","article-title":"Genetics, epigenetics, and genomics of systemic sclerosis","volume":"41","author":"Salazar","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2023080221015767700_kead014-B4","doi-asserted-by":"crossref","first-page":"e000134","DOI":"10.1136\/bmjgast-2017-000134","article-title":"Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts","volume":"4","author":"Volkmann","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"key":"2023080221015767700_kead014-B5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/2397198319891282","article-title":"Gastrointestinal involvement in systemic sclerosis: effects on morbidity and mortality and new therapeutic approaches","volume":"6","author":"Hoffmann-Vold","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"2023080221015767700_kead014-B6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2036.1992.tb00571.x","article-title":"Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis","volume":"6","author":"Hendel","year":"1992","journal-title":"Aliment Pharmacol Ther"},{"key":"2023080221015767700_kead014-B7","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1007\/BF02208652","article-title":"Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction","volume":"40","author":"Verne","year":"1995","journal-title":"Digest Dis Sci"},{"key":"2023080221015767700_kead014-B8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1084\/jem.20180448","article-title":"The gut microbiome: relationships with disease and opportunities for therapy","volume":"216","author":"Durack","year":"2019","journal-title":"J Exp Med"},{"key":"2023080221015767700_kead014-B9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/23971983211032808","article-title":"Fecal microbiome differs between patients with systemic sclerosis with and without small intestinal bacterial overgrowth","volume":"6","author":"Levin","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"2023080221015767700_kead014-B10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/acr2.11387","article-title":"Disease features and gastrointestinal microbial composition in patients with systemic sclerosis from two independent cohorts","volume":"4","author":"Andr\u00e9asson","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2023080221015767700_kead014-B11","doi-asserted-by":"crossref","first-page":"14874","DOI":"10.1038\/s41598-017-14889-6","article-title":"Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement","volume":"7","author":"Patrone","year":"2017","journal-title":"Sci Rep"},{"key":"2023080221015767700_kead014-B12","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.5152\/eurjrheum.2019.19103","article-title":"Gastrointestinal tract microbiota modifications in systemic sclerosis","volume":"7(Suppl 3)","author":"Volkmann","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"2023080221015767700_kead014-B13","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"Lancet"},{"key":"2023080221015767700_kead014-B14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/00365529850171666","article-title":"Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment","volume":"33","author":"Gustafsson","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"2023080221015767700_kead014-B15","doi-asserted-by":"crossref","first-page":"e0232739","DOI":"10.1371\/journal.pone.0232739","article-title":"Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial","volume":"15","author":"Fretheim","year":"2020","journal-title":"PLoS One"},{"key":"2023080221015767700_kead014-B16","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1136\/annrheumdis-2020-219511","article-title":"Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial","volume":"80","author":"Kragsnaes","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023080221015767700_kead014-B17","doi-asserted-by":"crossref","first-page":"524851","DOI":"10.3389\/fcimb.2021.524851","article-title":"The effects of fecal microbiota transplantation on the symptoms and the duodenal Neurogenin 3, Musashi 1, and enteroendocrine cells in patients with diarrhea-predominant irritable bowel syndrome","volume":"11","author":"Mazzawi","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2023080221015767700_kead014-B18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/cei.13397","article-title":"Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease","volume":"199","author":"Quraishi","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"2023080221015767700_kead014-B19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.24730","article-title":"Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument","volume":"61","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023080221015767700_kead014-B20","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/ard.2010.142489","article-title":"EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research","volume":"70","author":"Beyer","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023080221015767700_kead014-B21","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1093\/rheumatology\/keac118","article-title":"Gastrointestinal symptom severity and progression in systemic sclerosis","volume":"61","author":"van Leeuwen","year":"2022","journal-title":"Rheumatology"},{"key":"2023080221015767700_kead014-B22","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"Classification Criteria for Systemic Sclerosis: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"65","author":"Van Den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023080221015767700_kead014-B23","doi-asserted-by":"crossref","first-page":"841859","DOI":"10.3389\/fimmu.2022.841859","article-title":"Examination of IgG Fc receptor CD16A and CD64 expression by canine leukocytes and their ADCC activity in engineered NK cells","volume":"13","author":"Hullsiek","year":"2022","journal-title":"Front Immunol"},{"key":"2023080221015767700_kead014-B24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3389\/fimmu.2019.00805","article-title":"IgG and Fc\u03b3 receptors in intestinal immunity and inflammation","volume":"10","author":"Castro-Dopico","year":"2019","journal-title":"Front Immunol"},{"key":"2023080221015767700_kead014-B25","doi-asserted-by":"crossref","first-page":"e43361","DOI":"10.1371\/journal.pone.0043361","article-title":"Fc gamma receptor CD64 modulates the inhibitory activity of infliximab","volume":"7","author":"Wojtal","year":"2012","journal-title":"PLoS One"},{"key":"2023080221015767700_kead014-B26","doi-asserted-by":"crossref","first-page":"e0126007","DOI":"10.1371\/journal.pone.0126007","article-title":"CD38 is expressed on inflammatory cells of the intestine and promotes intestinal inflammation","volume":"10","author":"Schneider","year":"2015","journal-title":"PLoS One"},{"key":"2023080221015767700_kead014-B27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbrc.2017.10.114","article-title":"KLF2 attenuates bleomycin-induced pulmonary fibrosis and inflammation with regulation of AP-1","volume":"495","author":"Shi","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"2023080221015767700_kead014-B28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3390\/biomedicines9070791","article-title":"Roles of XBP1s in transcriptional regulation of target genes","volume":"9","author":"Park","year":"2021","journal-title":"Biomedicines"},{"key":"2023080221015767700_kead014-B29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.15252\/emmm.201505925","article-title":"Endoplasmic reticulum stress enhances fibrosis through IRE1\u03b1-mediated degradation of miR-150 and XBP-1 splicing","volume":"8","author":"Heindryckx","year":"2016","journal-title":"EMBO Mol Med"},{"key":"2023080221015767700_kead014-B30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3389\/fimmu.2018.01289","article-title":"IRE1\u03b1 implications in endoplasmic reticulum stress-mediated development and pathogenesis of autoimmune diseases","volume":"9","author":"Junjappa","year":"2018","journal-title":"Front Immunol"},{"key":"2023080221015767700_kead014-B31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.cell.2008.07.021","article-title":"XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease","volume":"134","author":"Kaser","year":"2008","journal-title":"Cell"},{"key":"2023080221015767700_kead014-B32","doi-asserted-by":"crossref","first-page":"G673","DOI":"10.1152\/ajpgi.00353.2013","article-title":"Downregulation of duodenal SLC transporters and activation of proinflammatory signaling constitute the early response to high altitude in humans","volume":"307","author":"Wojtal","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2023080221015767700_kead014-B33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11894-006-0019-3","article-title":"Biologic clocks and the gut","volume":"8","author":"Hoogerwerf","year":"2006","journal-title":"Curr Gastroenterol Rep"},{"key":"2023080221015767700_kead014-B34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1053\/gast.2000.9305","article-title":"Biological clocks and the digestive system","volume":"119","author":"Scheving","year":"2000","journal-title":"Gastroenterology"},{"key":"2023080221015767700_kead014-B35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/B978-0-12-405943-6.00010-5","article-title":"DEC1\/STRA13\/SHARP2 and DEC2\/SHARP1 coordinate physiological processes, including circadian rhythms in response to environmental stimuli","volume":"110","author":"Kato","year":"2014","journal-title":"Curr Top Dev Biol"},{"key":"2023080221015767700_kead014-B36","doi-asserted-by":"crossref","first-page":"727451","DOI":"10.3389\/fphys.2021.727451","article-title":"Distinct metalloproteinase expression and functions in systemic sclerosis and fibrosis: what we know and the potential for intervention","volume":"12","author":"Leong","year":"2021","journal-title":"Front Physiol"},{"key":"2023080221015767700_kead014-B37","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/rheumatology\/ker367","article-title":"Differential gene expression of MMP-1, TIMP-1 and HGF in clinically involved and uninvolved skin in South Africans with SSc","volume":"51","author":"Frost","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2023080221015767700_kead014-B38","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med"},{"key":"2023080221015767700_kead014-B39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/1744666X.2019.1707665","article-title":"The potential of fecal microbiota transplantation in systemic sclerosis","volume":"16","author":"Hoffmann-Vold","year":"2020","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead014\/50607316\/kead014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/8\/2918\/51026657\/kead014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/8\/2918\/51026657\/kead014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T21:03:00Z","timestamp":1691010180000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/8\/2918\/6998197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,1,23]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead014","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,1,23]]}}}